Angiotech appeal fails


The IPKat's friend Richard Evans (Informa Law) has pointed out that the appeal brought by Angiotech against a High Court ruling revoking their patent (EP0706376) relating to paclitaxel (Taxol)-coated stents has failed. Lord Justice Jacob, as usual taking the lead in the Court of Appeal on IP matters, has upheld Mr Justice Pumfrey's earlier decision finding Angiotech's patent invalid for being obvious. The decision is available from Bailii here, and the earlier High Court decision here.

According to IP World Online, Angiotech are not too upset about this setback, as they have other Taxol stent patents in their portfolio, which this decision does not apparently affect, and the EPO have upheld the patent in opposition proceedings. A quick check on the European Patent Office's epoline service shows that Angiotech in fact have no fewer than 10 other EP applications deriving from EP0706376, so will have another few cracks at the whip before all is lost. Also, Angiotech still have various parallel national patents in Europe including one in Holland, deriving from the same European application, which last year was upheld by a Dutch court.

Whether the UK courts are too strict on patentees or the EPO and other European courts are too lax is a difficult one to judge, and not an issue the IPKat feels comfortable commenting on. However, this is clearly one of those cases where the decision is finely balanced and can easily go either way. As far as Angiotech are concerned though, this is clearly one that is well worth fighting all the way for.
Angiotech appeal fails Angiotech appeal fails Reviewed by David Pearce on Tuesday, January 16, 2007 Rating: 5

3 comments:

  1. In terms of comparison between UK and EPO practice, it looks as if this UK case was running in parallel with opposition proceedings in the EPO, which at first instance revoked the patent. So I'm not sure this highlights a different practice between the two offices/courts.

    It would only go to court if it were a borderline case, so a degree of disagreement is not surprising.

    ReplyDelete
  2. Paclitaxel has some interesting patents associated with it; in particular, the key inventive step of one patent is challenged and contradicted in the preamble of another patent!

    ReplyDelete
  3. What I find interesting in this case is whether the EPO problem and solution approach, correctly applied, would deliver the "obvious" result arrived at in England, or the "not obvious" answer delivered (so far) in Den Haag. But, as the TBA is only looking at admissibility, in its oral proceedings in March, we may never know what the TBA thinks about Art 56.

    ReplyDelete

All comments must be moderated by a member of the IPKat team before they appear on the blog. Comments will not be allowed if the contravene the IPKat policy that readers' comments should not be obscene or defamatory; they should not consist of ad hominem attacks on members of the blog team or other comment-posters and they should make a constructive contribution to the discussion of the post on which they purport to comment.

It is also the IPKat policy that comments should not be made completely anonymously, and users should use a consistent name or pseudonym (which should not itself be defamatory or obscene, or that of another real person), either in the "identity" field, or at the beginning of the comment. Current practice is to, however, allow a limited number of comments that contravene this policy, provided that the comment has a high degree of relevance and the comment chain does not become too difficult to follow.

Learn more here: http://ipkitten.blogspot.com/p/want-to-complain.html

Powered by Blogger.